BeOne Medicines Ltd.
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302313% above fair value
$361.27−9.06 (-2.45%)
Close on Nov 2, 2026Market cap $41.08BP/E 64.6Yield –
BeOne Medicines Total External R&D Expense by Quarter
Total External R&D Expense ($M) ($M)
BeOne Medicines Total External R&D Expense: $248M in Q2 2026, up 18.2% from a year earlier.
Latest, Q2 2026
248
Period ended Jun 30, 2026
Change on a year earlier
+18.2%
210 in Q2 2025
History
26 quarters
Since Q1 2020
Sources
22
Documents cited below
Where the Q2 2026 figure comes from
“|| Total external research and development expenses | 247,622 | 209,506 | 38,116 | 18.2 | %”
Source: Form 10-Q (filed 2026-08-05) ↗
Reported in Form 10-Q / 10-K MD&A R&D Expense Summary Table.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up total External R&D Expense
Cite this data
StockData. (2026). BeOne Medicines Total External R&D Expense ($M), quarterly Q1 2020–Q2 2026 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/rd-external-tot
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.